Abstract
Selective degradation of proteins by the ubiquitin-proteasome pathway is a critical determinant for maintaining cellular homeostasis. Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. Many proteasome target proteins are involved in the regulation of important processes of carcinogenesis and cancer cell survival, such as cell cycle progression, cell proliferation, differentiation and apoptosis. Indeed, the ubiquitin-proteasome-dependent degradation pathway plays an essential role in both the up-regulation of cell proliferation and down-regulation of cell death in human cancer cells. Both in vitro and in vivo experimental and clinical results have demonstrated the potential use of proteasome inhibitors as novel anticancer drugs. Proteasome inhibition in cancer cells leads to accumulation of pro-apoptotic target proteins followed by induction of cell death. The clinical efficacy of the proteasome inhibitor bortezomib toward multiple myeloma and other hematologic malignancies provides the “proof of concept” that targeting the proteasome is a promising strategy for cancer treatment. Several other proteasome inhibitors have also been identified from natural resources, such as marine microbial metabolites, green tea polyphenols, flavonoids, and medicinal compounds. Additionally, the use of metal complexes as proteasome inhibitors has also been investigated as a potential anticancer strategy. The clinical significance of targeting the tumor survival-associated proteasome pathway for cancer treatment, intervention and prevention will be discussed.
Keywords: Proteasome, apoptosis, bortezomib, natural compounds, nutrition agents, metals, cell cycle progression, potential anticancer strategy, natural compounds and metal complexes, novel proteasome inhibitors, chemopreventative effects, potential anti-cancer drugs, ubiquitin-ligating enzyme, von Hippel-Linendau protein (pVHL), multiple myeloma (MM)
Current Topics in Medicinal Chemistry
Title: Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Volume: 11 Issue: 23
Author(s): Michael Frezza, Sara Schmitt and Q. Ping Dou
Affiliation:
Keywords: Proteasome, apoptosis, bortezomib, natural compounds, nutrition agents, metals, cell cycle progression, potential anticancer strategy, natural compounds and metal complexes, novel proteasome inhibitors, chemopreventative effects, potential anti-cancer drugs, ubiquitin-ligating enzyme, von Hippel-Linendau protein (pVHL), multiple myeloma (MM)
Abstract: Selective degradation of proteins by the ubiquitin-proteasome pathway is a critical determinant for maintaining cellular homeostasis. Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. Many proteasome target proteins are involved in the regulation of important processes of carcinogenesis and cancer cell survival, such as cell cycle progression, cell proliferation, differentiation and apoptosis. Indeed, the ubiquitin-proteasome-dependent degradation pathway plays an essential role in both the up-regulation of cell proliferation and down-regulation of cell death in human cancer cells. Both in vitro and in vivo experimental and clinical results have demonstrated the potential use of proteasome inhibitors as novel anticancer drugs. Proteasome inhibition in cancer cells leads to accumulation of pro-apoptotic target proteins followed by induction of cell death. The clinical efficacy of the proteasome inhibitor bortezomib toward multiple myeloma and other hematologic malignancies provides the “proof of concept” that targeting the proteasome is a promising strategy for cancer treatment. Several other proteasome inhibitors have also been identified from natural resources, such as marine microbial metabolites, green tea polyphenols, flavonoids, and medicinal compounds. Additionally, the use of metal complexes as proteasome inhibitors has also been investigated as a potential anticancer strategy. The clinical significance of targeting the tumor survival-associated proteasome pathway for cancer treatment, intervention and prevention will be discussed.
Export Options
About this article
Cite this article as:
Frezza Michael, Schmitt Sara and Ping Dou Q., Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy, Current Topics in Medicinal Chemistry 2011; 11 (23) . https://dx.doi.org/10.2174/156802611798281311
DOI https://dx.doi.org/10.2174/156802611798281311 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Cellomics as Integrative Omics for Cancer
Current Proteomics Hematopoietic Cell Formation in Leech Wound Healing
Current Pharmaceutical Design Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry A Personalized Approach to Systemic Treatment of Unresectable or Metastatic Pancreatic Adenocarcinoma
Current Pharmacogenomics and Personalized Medicine The Expanding Role of APRIL in Cancer and Immunity
Current Molecular Medicine Invasive Aspergillosis: Focus on New Approaches and New Therapeutic Agents
Current Medicinal Chemistry - Anti-Infective Agents Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Current Medicinal Chemistry Molecular Targeting in Pancreatic Cancer
Reviews on Recent Clinical Trials Teaching Pharmacogenetics in Low and Middle-Income Countries: Team Based Learning and Lessons Learned at the American University of Beirut
Current Pharmacogenomics and Personalized Medicine Quality of Life in Patients with β-thalassemia Major: Short-term and Long-term Effects After Haematopoietic Stem Cell Transplantation
Current Stem Cell Research & Therapy Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening Intracellular and Extracellular miRNAs in Regulation of Angiogenesis Signaling
Current Angiogenesis (Discontinued) Perinatal Gene Transfer to the Liver
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued)